Immunotherapy: analyses elucidating durvalumab & pembrolizumab activity
Immunotherapy: analyses elucidating durvalumab &
Current perspectives in EGFR-targeted therapy
Current perspectives in EGFR-targeted therapy
Anti-angiogenic combinations excel in later lines
Anti-angiogenic combinations excel in later line
Interview: “We need chemotherapy when rapid responses are required”
Interview: “We need chemotherapy when rapid resp
Extensive-disease small-cell tumors: signals of activity
Extensive-disease small-cell tumors: signals of
Interview: Improving accuracy of lung cancer screening
Interview: Improving accuracy of lung cancer scr
Encouraging findings in NTRK-, ROS1– and ALK-positive lung cancer
Encouraging findings in NTRK-, ROS1– and ALK-pos
Preface – ELCC 2019
Preface – ELCC 2019 Pilar Garrido, MD, PhD H
